在慢性病中抑制阿尔多氨酸合成酶
Marieta P Theodorakopoulou1, Fotini Iatridi, Pantelis A Sarafidis
1First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Current opinion in nephrology and hypertension
|May 2, 2025
概括
新的阿尔多合成酶抑制剂 (ASIs) 显示出降低慢性病 (CKD) 患者心风险的潜力. 这些药物直接抑制阿尔多斯特的产生,提供了超越当前治疗的潜在新策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 慢性病 (CKD) 具有显著的心血管风险和进展到衰竭.
- 目前的治疗方法,如氨酸 - ангиотензин系统抑制剂和SGLT2抑制剂,不能完全减轻残留心脏病风险.
- 过度激活阿尔多路径是导致这种残留风险的关键因素.
研究的目的:
- 在CKD中探索更广泛的阿尔多素通路抑制,超出现有疗法.
- 评估非类固醇矿物质皮质类受体对抗剂 (MRA) 和阿尔多合成酶抑制剂 (ASI) 在控制心脏病风险方面的疗效.
主要方法:
- 审查CKD当前的治疗策略及其局限性.
- 对非类固醇MRAs (包括finerenone) 的临床数据的分析.
- 检查CKD人群中阿尔多合成酶抑制剂 (ASIs) 的新兴数据.
主要成果:
- 非类固醇MRAs,像finerenone一样,提供心脏和脏的好处,但有局限性.
- 阿尔多合成酶抑制剂 (ASIs) 直接抑制阿尔多的产生,在早期CKD研究中显示出有前途.
- 在最初的试验中,ASIs证明了白蛋白尿和血压的降低,在最初的试验中具有有利的安全性.
结论:
- 直接抑制阿尔多素合成是一种新的策略,可以减少CKD的残留心脏脏风险.
- 阿尔多氨酸合成酶抑制剂 (ASIs) 可以补充现有的治疗方法.
- 进一步的第三阶段试验对于确定ASIs在CKD管理中的临床效用和整合至关重要.
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
398
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
398
01:25Antihypertensive Drugs: Direct Renin Inhibitors
439
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
439
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
302
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
302
01:33Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
376
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
376
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
529
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
529